After Failed COVID-19 Drug Trial, Atea Pharmaceuticals Touts Encouraging Data From Mid-Stage Hepatitis C Study
AVIR achieved 98% SVR12 in treatment adherent patients after 8 weeks. Safety study indicates no serious adverse events from the regimen. Phase 3 program expected to improve patient convenience with fewer pills. Regimen demonstrated efficacy even in patients with cirrhosis (88% SVR12). AVIR stock is currently down 9.63% despite positive study results.
View signal analysis